Diaceutics (FRA:7DC) Accounts Payable: €1.76 Mil (As of Dec. 2025)


FRA:7DC Diaceutics PLC FRA:7DC
91 GF Score
Price €1.62
GF Value €2.15
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Diaceutics Accounts Payable?

Diaceutics FRA:7DC 91 Accounts Payable is €1.76 Mil as of Dec. 2025. GuruFocus rates FRA:7DC with a GF Score™ of 91/100 and a GF Value™ of €2.15 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Diaceutics's Accounts Payable for the quarter that ended in Dec. 2025 was €1.76 Mil.

Diaceutics's quarterly Accounts Payable declined from Dec. 2024 (€1.47 Mil) to Jun. 2025 (€1.26 Mil) but then increased from Jun. 2025 (€1.26 Mil) to Dec. 2025 (€1.76 Mil).

Diaceutics's annual Accounts Payable increased from Dec. 2023 (€1.24 Mil) to Dec. 2024 (€1.47 Mil) and increased from Dec. 2024 (€1.47 Mil) to Dec. 2025 (€1.76 Mil).

Diaceutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Diaceutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diaceutics Accounts Payable Chart

Diaceutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.60 0.87 1.24 1.47 1.76

Diaceutics Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.24 0.72 1.47 1.26 1.76
FRA:7DC
91GF Score
Diaceutics PLC FRA:7DC
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diaceutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €1.76 Mil mean?
Diaceutics (FRA:7DC) has a Accounts Payable of €1.76 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Diaceutics and its competitors.
Is Diaceutics' Accounts Payable too high?
Diaceutics' current Accounts Payable is €1.76 Mil. Overall, Diaceutics has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diaceutics' Accounts Payable compare to VEEV and BTSG?
Diaceutics' Accounts Payable of €1.76 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Healthcare Providers & Services company?
A good Accounts Payable depends on the Healthcare Providers & Services industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Diaceutics and its competitors. Diaceutics's current Accounts Payable is €1.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diaceutics stock overvalued right now?
Based on GuruFocus' analysis, Diaceutics (FRA:7DC) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.15, compared to a current price of €1.62 — trading 24.7% below its estimated fair value. The current Accounts Payable is €1.76 Mil. Diaceutics' overall GF Score™ is 91/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Diaceutics (FRA:7DC), the current Accounts Payable is €1.76 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diaceutics (FRA:7DC) Overvalued in 2026?

Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued. The current stock price of €1.62 is trading 24.7% below its estimated GF Value™ of €2.15. GuruFocus considers Diaceutics to be Modestly Undervalued.

Key valuation signals for FRA:7DC:

  • Accounts Payable: €1.76 Mil
  • GF Value™: €2.15 vs. price of €1.62 (24.7% below fair value)
  • GF Score™: 91/100 with 1 warning sign

No single metric tells the full story. See the FRA:7DC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diaceutics Business Description

Other Exchanges DIUXF:USADXRX:UK
Address Dataworks at Kings Hall Health & Wellbeing Park, First Floor, Building Two, County Antrim, Belfast, GBR, BT9 6GW
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.
91GF Score

Get the complete analysis for FRA:7DC

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.62
Price
€2.15
GF Value